IVRN (Innoveren Scientific) EBIT: $-2.82 Mil (TTM As of Sep. 2023)


IVRN Innoveren Scientific Inc IVRN
16 GF Score
Price $0.00
View Full Analysis

What is Innoveren Scientific EBIT?

Innoveren Scientific IVRN 16 EBIT is $-2.82 Mil as of Sep. 2023. GuruFocus rates IVRN with a GF Score™ of 16/100.

Innoveren Scientific's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-0.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.82 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innoveren Scientific's annualized ROC % for the quarter that ended in Sep. 2023 was -29.58%. Innoveren Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -9,600.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Innoveren Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -94,033.33%.


Innoveren Scientific  (OTCPK:IVRN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Innoveren Scientific's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-1.684 * ( 1 - 0% )/( (5.252 + 6.134)/ 2 )
=-1.684/5.693
=-29.58 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Innoveren Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.584/( ( (0.017 + max(-4.005, 0)) + (0.016 + max(-5.084, 0)) )/ 2 )
=-1.584/( ( 0.017 + 0.016 )/ 2 )
=-1.584/0.0165
=-9,600.00 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.14) - (3.414 + 0 + 0.731)
=-4.005

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.139) - (3.567 + 0.925 + 0.731)
=-5.084

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Innoveren Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-2.821/0.003
=-94,033.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoveren Scientific EBIT Related Terms


Innoveren Scientific EBIT Historical Data

* Premium members only.

The historical data trend for Innoveren Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoveren Scientific EBIT Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.75 -29.51 -5.00 -4.62 -9.93

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -1.40 -1.94 0.92 -0.40

IVRN vs GNCA, ISCO, FNAM: EBIT Comparison

For the Biotechnology subindustry, Innoveren Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoveren Scientific EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's EV-to-EBIT falls into.


IVRN
16GF Score
Innoveren Scientific Inc IVRN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innoveren Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-2.82 Mil mean?
Innoveren Scientific (IVRN) has a EBIT of $-2.82 Mil as of Sep. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Innoveren Scientific.
Is Innoveren Scientific's EBIT too high?
Innoveren Scientific's current EBIT is $-2.82 Mil. Overall, Innoveren Scientific has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Innoveren Scientific's EBIT compare to GNCA and ISCO?
Innoveren Scientific's EBIT of $-2.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Innoveren Scientific. Innoveren Scientific's current EBIT is $-2.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoveren Scientific stock overvalued right now?
Innoveren Scientific (IVRN) has a current EBIT of $-2.82 Mil. The current EBIT is $-2.82 Mil. Innoveren Scientific's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Innoveren Scientific (IVRN), the current EBIT is $-2.82 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innoveren Scientific Business Description

Address 2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
16GF Score

Get the complete analysis for IVRN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price